Slide 1: Conference Call Preliminary Full-Year 2020 Results
Conference Call Preliminary Full-Year 2020 Results Joachim Kreuzburg, Rainer Lehmann Sartorius | Sartorius Stedim Biotech January 27, 2021
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee tha
Slide 3: Highlights
Highlights Strong finish to the year in both Group divisions 2020 preliminary figures show double digit growth across the board Bioprocess Solutions Division: Continued high underlying demand; plays a key role as a provider for vaccine technologies Lab Products & Services Division: First hal
Slide 4: Agenda
Agenda Sartorius Group FY 2020 results | FY 2021 guidance | 2025 ambition Sartorius Stedim Biotech Group FY 2020 results | FY 2021 guidance | 2025 ambition Questions & Answers 4
Slide 5: Strong profitable growth
Strong profitable growth Sartorius Group 2019 2020 in % in % cc1 in millions of € unless otherwise specified Sales revenue 1,827.0 2,335.7 +27.8 +30.2 Order intake 1,939.5 2,836.3 +46.2 +49.0 Underlying EBITDA2 495.8 692.2 +39.6 Underlying EBITDA2 margin in % 27.1 29.6 +2.5pp Underlying EPS3 (ord.)
Slide 6: Double-digit sales growth in all geographies
Double-digit sales growth in all geographies Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % +32.8% +28.4% +29.6% EMEA 935.1 ~ 40% Americas 812.2 733.4 ~ 35% 629.9 588.4 463.7 €2,335.7m Asia|Pacific 2019 2020 2019 2020 2019 2020 ~ 25% Americas: BPS benefit
Slide 7: BPS: Dynamic growth across all product categories and regions
BPS: Dynamic growth across all product categories and regions Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +56.4% cc + 34.4% cc +53.5% +32.0% +46.5% 2,238.1 1,782.6 575.9 1,457.6 1,350.5 393.1 32.3% 29.1% 2019 1 2020 2019 1 2020 2019 1 2020 Strong
Slide 8: LPS: Rebound and catch-up effects after challenging first half
LPS: Rebound and catch-up effects after challenging first half Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +26.4% cc +18.1% cc +13.2% +24.1% +16.1% 598.2 553.0 481.9 476.5 116.3 102.7 21.6% 21.0% 20191 2020 20191 2020 2019 1 2020 In particular, h
Slide 9: Operating cash flow increases significantly
Operating cash flow increases significantly Sartorius Group Net operating cash flow mostly driven by higher 2019 2020 in % earnings and factoring program (~€89m) in millions of € unless otherwise specified Underlying EBITDA 495.8 692.2 +39.6 Extraordinary items influenced primarily by M&A Extrao
Slide 10: Financial indicators remain on very solid level
Financial indicators remain on very solid level Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Dec. 31, Dec. 31, Sartorius Group 2,000 4.0 2019 2020 1,500 3.0 Equity ratio in % 38.1 29.9 1,000 2.0 Net debt in millions of € 1,014.0 1,883.6 500 1.0 0 0.0 Net debt | underlying 2.0
Slide 11: Most recent acquisitions broadening the downstream portfolio
Most recent acquisitions broadening the downstream portfolio Acquisition of WaterSep BioSeparations Agreement to acquire chromatography process equipment division from Novasep Dec. ~$2.5m + 15 ~€37m + 100 H1 2021 2020 Sales revenue Employees Date of Sales revenue Employees Closing in 2020e consolida
Slide 12: Strong outlook for 2021, uncertainties remain high
Strong outlook for 2021, uncertainties remain high 2020 2021 Guidance 1 Sales Revenue Underlying Sales Revenue Underlying Growth EBITDA Margin Growth EBITDA Margin Sartorius Group +30.2% 29.6% ~ 19% - 25% ~ 30.5% - growth by acquisitions | Corona demand good 7pp | good 8pp ~5.5pp | up to 6pp Bioproc
Slide 13: 2025 ambition – increased baseline and organic growth
2025 ambition – increased baseline and organic growth Initial 2025 group sales revenue targets were based on an estimated 2020 group revenue of €2bn, based on the mid-term guidance of 2012 Expectation was to double the revenue target to €4bn within 5 years Actual 2020 Group revenue was approx.
Slide 14: Updated 2025 ambition
Updated 2025 ambition BPS LPS Sartorius Group Sales ~€3.8bn ~€1.2bn €5bn revenue previously ~€2.8bn unchanged previously ~€4bn EBITDA ~34% ~25% ~32% margin previously ~30% unchanged previously ~28% 2025 targets are based on 2020 currency exchange rates; EBITDA excluding extraordinary items 14
Slide 15: Corporate responsibility & further financial information
Corporate responsibility & further financial information To Sartorius, sustainability means operating Please click below for further financial information: responsibly over the long term – with respect to business partners, employees and society as well as to Annual Report 2020 natural resources. Le
Slide 16: Agenda
Agenda Sartorius Group FY 2020 results | FY 2021 guidance | 2025 ambition Sartorius Stedim Biotech Group FY 2020 results | FY 2021 guidance | 2025 ambition Questions & Answers 16
Slide 17: Exceptionally strong growth in 2020
Sartorius Stedim Biotech Group Exceptionally strong growth in 2020 Sartorius Stedim Biotech Group 2019 2020 in % in % cc1 in millions of € unless otherwise specified Sales revenue 1,440.6 1,910.1 +32.6 +34.6 Order intake 1,543.5 2,381.0 +54.3 +56.7 Underlying EBITDA2 421.5 604.7 +43.5 Underlying EBI
Slide 18: Double-digit sales growth in all geographies
Sartorius Stedim Biotech Group Double-digit sales growth in all geographies Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % +34.0% +33.0% +38.3% EMEA ~ 40% Americas 670.2 761.0 ~ 35% 511.6 575.1 478.9 €1,910.1m 353.8 Asia|Pacific ~ 25% 2019 2020 2019 2020 20
Slide 19: Operating cash flow rises significantly
Sartorius Stedim Biotech Group Operating cash flow rises significantly Sartorius Stedim Biotech Group Net operating cash flow mostly driven by 2019 2020 in % higher earnings and factoring program (~€76m) in millions of € unless otherwise specified Underlying EBITDA 421.5 604.7 +43.5 Extraordinar
Slide 20: Financial indicators remain on very solid level
Sartorius Stedim Biotech Group Financial indicators remain on very solid level Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA 600 1.8 Dec. 31, Dec. 31, Sartorius Stedim Biotech 2019 2020 500 1.5 400 1.2 Equity ratio in % 64.4 48.3 300 0.9 200 0.6 Net debt in millions of € 110.4
Slide 21: Strong outlook for 2021, uncertainties remain high
Sartorius Stedim Biotech Group Strong outlook for 2021, uncertainties remain high FY 2021 Guidance1 Sales revenue growth Underlying EBITDA margin 2020 2021 2020 2021 Sartorius Stedim Biotech 34.6% ~ 20-26% 31.7% ~ 32.0% - growth by acquisitions | Corona demand close to 6pp | good 12pp ~5.5pp | up to
Slide 22: 2025 ambition – increased baseline and organic growth
Sartorius Stedim Biotech Group 2025 ambition – increased baseline and organic growth Initial 2025 group sales revenue targets were based Sartorius Stedim Biotech on an estimated 2020 group revenue of €1.5 to 1.6bn, based on the mid-term guidance of 2012 Actual 2020 Group revenue was approx. €1.9
Slide 23: Corporate responsibility & further financial information
Sartorius Stedim Biotech Group Corporate responsibility & further financial information To Sartorius Stedim Biotech, sustainability means Please click below for further financial information: operating responsibly over the long term – with respect to business partners, employees and society as well
Slide 24: Questions & Answers
Questions & Answers 24